193. Efficacy and safety of adjunctive lumateperone 42 mg in major depressive disorder: pooled analysis of demographic and clinical subgroups from Phase 3 randomized placebo-controlled trials
Abstract Background Major depressive disorder (MDD) presents with highly variable clinical symptoms and treatment responses. Patient characteristics can impact treatment outcomes, making it essential to evaluate efficacy across subgroups to establish consistency of treatment effects. Lumateperone is an FDA-approved ant...